Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Breaking Down The Barrier: Topical Liposomes As Nanocarriers For Drug Delivery Into The Posterior Segment Of The Eyeball

A. Santos, J. C. Altamirano-Vallejo, José Navarro-Partida, Alejandro González-de la Rosa, J. Hsiao
Published 2019 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
This paper references
10.1211/jpp.59.5.0002
Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops
T. Loftsson (2007)
10.1136/bjo.2006.099598
The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide
A. Fung (2006)
10.1007/s13346-016-0339-2
A comprehensive insight on ocular pharmacokinetics
Vibhuti Agrahari (2016)
10.1016/j.ejpb.2012.10.014
Retinal drug delivery using eyedrop preparations of poly-L-lysine-modified liposomes.
Hitoshi Sasaki (2013)
10.3109/08982104.2013.796975
Transdermal delivery of butamben using elastic and conventional liposomes
Cintia Maria Saia Cereda (2013)
10.4103/0974-620X.200692
Applications of polymers in intraocular drug delivery systems
A. Alhalafi (2017)
10.1167/IOVS.02-0956
Intraocular tissue distribution of betamethasone after intrascleral administration using a non-biodegradable sustained drug delivery device.
Komei Okabe (2003)
10.3109/10717544.2014.943336
Liposomes in topical ophthalmic drug delivery: an update
R. Agarwal (2016)
10.1016/S0161-6420(03)00085-X
Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results.
D. Guyer (2003)
10.1517/17425247.3.2.275
Ocular drug delivery
D. Ghate (2006)
10.4103/0250-474X.57282
Solid Lipid Nanoparticles: A Modern Formulation Approach in Drug Delivery System
S. Mukherjee (2009)
10.2174/1570161033386826
Migraine: pathophysiology, pharmacology, treatment and future trends.
C. Villalón (2003)
10.1089/jop.2018.0101
Novel Triamcinolone Acetonide-Loaded Liposomes Topical Formulation for the Treatment of Cystoid Macular Edema After Cataract Surgery: A Pilot Study
Alejandro Gonzalez-De la Rosa (2019)
10.1167/IOVS.04-0601
Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.
J. Gaudreault (2005)
10.1136/bmjopen-2014-005244
The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review
E. Poku (2014)
10.1002/jps.24588
In Vitro/In Vivo Evaluation of Dexamethasone--PAMAM Dendrimer Complexes for Retinal Drug Delivery.
B. Yavuz (2015)
10.1039/c2nr32923a
Cholesterol--a biological compound as a building block in bionanotechnology.
L. Hosta-Rigau (2013)
10.2147/NANO.2007.2.1.65
Age-related macular degeneration: a target for nanotechnology derived medicines
D. Birch (2007)
10.1167/iovs.11-7983
Edaravone-loaded liposome eyedrops protect against light-induced retinal damage in mice.
Hiroki Shimazaki (2011)
10.46956/IJIHD.VI.116
Liposomes: A review
S. Shailesh (2020)
10.2147/IJN.S138267
Elastic liposomes as novel carriers: recent advances in drug delivery
A. Hussain (2017)
10.1046/J.1442-9071.2001.00360.X
Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis
S. Young (2001)
10.1016/j.jpba.2010.01.015
Development and validation of a fast and sensitive bioanalytical method for the quantitative determination of glucocorticoids--quantitative measurement of dexamethasone in rabbit ocular matrices by liquid chromatography tandem mass spectrometry.
R. Earla (2010)
10.1089/JOP.2005.21.1
Transscleral permeability of fluorescent-labeled antibiotics.
James C Kao (2005)
10.1023/A:1015896121377
Nebulization of Liposomes. II. The Effects of Size and Modeling of Solute Release Profiles
R. Niven (2004)
10.1211/jpp.57.12.0005
Size‐dependent disposition of nanoparticles and microparticles following subconjunctival administration
A. Amrite (2005)
10.1166/JBN.2011.1333
Penetration enhancement of lidocaine hydrochlorid by a novel chitosan coated elastic liposome for transdermal drug delivery.
L. Li (2011)
10.1016/j.ijpharm.2012.07.024
Liposomal diclofenac eye drop formulations targeting the retina: formulation stability improvement using surface modification of liposomes.
Takuya Fujisawa (2012)
10.1186/1556-276X-8-102
Liposome: classification, preparation, and applications
A. Akbarzadeh (2013)
10.2174/138920111794480651
Fluocinolone acetonide implantable device for diabetic retinopathy.
S. G. Schwartz (2011)
10.1248/BPB.34.894
Fluorescence investigation of the retinal delivery of hydrophilic compounds via liposomal eyedrops.
K. Hironaka (2011)
10.1016/S0161-6420(02)01125-9
Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement.
J. Smith (2002)
10.1167/iovs.09-4697
Physicochemical properties affecting retinal drug/coumarin-6 delivery from nanocarrier systems via eyedrop administration.
Y. Inokuchi (2010)
10.1073/PNAS.85.18.6949
Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.
A. Gabizon (1988)
10.1016/j.neuroscience.2004.05.029
Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration
R. Thorne (2004)
10.1111/j.1755-3768.2010.02064.x
Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections
C. Meyer (2011)
10.1007/s00417-012-2177-3
Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life
Katharina M. Droege (2012)
10.3390/molecules23020288
Liposomes: Clinical Applications and Potential for Image-Guided Drug Delivery
Narottam Lamichhane (2018)
10.1089/108076804773710830
Scleral permeability of a small, single-stranded oligonucleotide.
R. Shuler (2004)
10.1016/j.jconrel.2012.01.032
Sustained release micellar carrier systems for iontophoretic transport of dexamethasone across human sclera.
P. Chopra (2012)
10.4155/tde.12.122
Nanomicelles: an emerging platform for drug delivery to the eye.
A. D. Vadlapudi (2013)
10.1533/9781908818317.37
Biology of ocular transporters: efflux and influx transporters in the eye
Pal Dhananjay (2013)
10.1016/J.ADDR.2005.09.005
Intraocular sustained drug delivery using implantable polymeric devices.
T. Yasukawa (2005)
10.1016/j.plipres.2017.07.001
Beyond liposomes: Recent advances on lipid based nanostructures for poorly soluble/poorly permeable drug delivery.
M. C. Teixeira (2017)
10.2147/IJN.S24326
Preparation and in vitro evaluation of doxorubicin-loaded Fe3O4 magnetic nanoparticles modified with biocompatible copolymers
A. Akbarzadeh (2012)
10.1016/0378-5173(92)90015-T
Drug encapsulation and release from multilamellar and unilamellar liposomes
G. Betageri (1992)
10.1016/j.ijpharm.2015.08.088
Lipid-polyethylene glycol based nano-ocular formulation of ketoconazole.
Shilpa Kakkar (2015)
10.1517/17425247.5.5.567
Ocular novel drug delivery: impacts of membranes and barriers
J. Barar (2008)
10.1111/J.1600-0749.1993.TB00591.X
Interaction between chemicals and melanin.
B. S. Larsson (1993)
10.1111/jphp.12104
Dendrimers for gene delivery – a potential approach for ocular therapy?
Sahil P. Chaplot (2014)
10.1097/00006982-200512000-00011
EFFECTIVE TRANSSCLERAL DELIVERY OF TWO RETINAL ANTI-ANGIOGENIC MOLECULES: Carboxyamido-triazole (CAI) and 2-Methoxyestradiol (2ME2)
L. P. Cruysberg (2005)
10.1159/000108117
Transport Barriers in Transscleral Drug Delivery for Retinal Diseases
S. Kim (2007)
10.1089/108076802321021108
In vitro human scleral permeability of fluorescein, dexamethasone-fluorescein, methotrexate-fluorescein and rhodamine 6G and the use of a coated coil as a new drug delivery system.
L. P. Cruysberg (2002)
10.1007/s12325-011-0019-z
The dexamethasone drug delivery system: Indications and evidence
N. London (2011)
10.1080/10717544.2019.1571122
A more efficient ocular delivery system of triamcinolone acetonide as eye drop to the posterior segment of the eye
J. Li (2019)
10.5497/WJP.V2.I2.47
Ocular drug delivery systems: An overview.
Ashaben D. Patel (2013)
10.1002/smll.201303433
Topical delivery of Avastin to the posterior segment of the eye in vivo using annexin A5-associated liposomes.
Benjamin M. Davis (2014)
10.1016/S0264-410X(98)00488-5
DNA-based non-invasive vaccination onto the skin.
Z. Shi (1999)
10.1089/jop.2012.0044
A preliminary evaluation of dexamethasone palmitate emulsion: a novel intravitreal sustained delivery of corticosteroid for treatment of macular edema.
Philippe Daull (2013)
10.1089/JOP.1986.2.67
Topical ocular drug delivery: recent developments and future challenges.
V. Lee (1986)
10.1111/j.1755-3768.1985.tb06829.x
The effect of ocular pigmentation on intraocular pressure responce to timolol
L. Salminen (1985)
10.1016/j.jtos.2014.10.003
Barrier function in the ocular surface: from conventional paradigms to new opportunities.
Y. Leong (2015)
10.1158/1078-0432.CCR-07-1441
Therapeutic Nanoparticles for Drug Delivery in Cancer
Kwangjae Cho (2008)
10.1016/j.ijpharm.2015.12.037
Topical delivery of aqueous micellar resolvin E1 analog (RX-10045).
K. Cholkar (2016)
10.1016/j.ophtha.2009.11.024
Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert.
P. Campochiaro (2010)
10.1159/000486145
2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations
A. Grzybowski (2018)
10.1006/RTPH.1998.1243
Binding of drugs to eye melanin is not predictive of ocular toxicity.
B. Leblanc (1998)
10.1016/J.ADDR.2005.09.004
Topical and systemic drug delivery to the posterior segments.
Patrick M Hughes (2005)
10.5402/2012/738432
Optimizing Druggability through Liposomal Formulations: New Approaches to an Old Concept
Dimitrios Bitounis (2012)
Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model.
G. Storm (1987)
10.1248/YAKUSHI.12-00234-3
[Non-invasive ophthalmic liposomes for nucleic acid delivery to posterior segment of eye].
Y. Takashima (2012)
10.1016/S1569-2590(05)10012-3
Drug Delivery to the Eye
A. Mitra (2005)
10.1167/IOVS.06-0954
Pharmacokinetics of intraocular drug delivery by periocular injections using ocular fluorophotometry.
D. Ghate (2007)
10.1007/s13318-016-0319-4
Ocular Drug Distribution After Topical Administration: Population Pharmacokinetic Model in Rabbits
Nassim Djebli (2016)
10.1111/aos.12803
Topical dexamethasone γ‐cyclodextrin nanoparticle eye drops increase visual acuity and decrease macular thickness in diabetic macular oedema
A. Ohira (2015)
10.3109/02652048609049580
A solid colloidal drug delivery system for the eye: encapsulation of pilocarpin in nanoparticles.
T. Harmia (1986)
10.1021/acsami.6b04551
Facile Noninvasive Retinal Gene Delivery Enabled by Penetratin.
Chengde Liu (2016)
10.1167/IOVS.06-0404
Bovine and porcine transscleral solute transport: influence of lipophilicity and the Choroid-Bruch's layer.
N. Cheruvu (2006)
10.1016/j.colsurfb.2011.06.025
Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye.
J. Araújo (2011)
10.3109/03639045.2014.938658
Elastic liposomes-in-vehicle formulations destined for skin therapy: the synergy between type of liposomes and vehicle
Zora Palac (2015)
10.4103/0301-4738.36479
The economic implications of the use of anti-vascular endothelial growth factor drugs in age-related macular degeneration
R. Azad (2007)
10.1167/IOVS.04-0925
Functional characterization and comparison of the outer blood-retina barrier and the blood-brain barrier.
Heiko Steuer (2005)
10.1038/sj.gt.3301485
In vivo gene delivery into ocular tissues by eye drops of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) polymeric micelles
J. Liaw (2001)
10.1016/S1554-4516(06)04002-6
Chapter 2: Surface Properties of Liposomes Depending on Their Composition
K. Makino (2006)
10.1016/0378-5173(86)90053-0
Enhancement of the myotic response of rabbits with pilocarpine-loaded polybutylcyanoacrylate nanoparticles
T. Harmia (1986)
Vesicular systems for non-invasive topical immunization: Rationale and prospects
R. Singh (2002)
10.1016/J.OHC.2004.06.010
Anterior segment complications following periocular and intraocular injections.
A. Castellarin (2004)
10.1021/mp200394t
Nanomedicine(s) under the microscope.
R. Duncan (2011)
10.1038/nrd3745
Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma
K. Zhang (2012)
10.1159/000050849
Biodegradable Polymers for Ocular Drug Delivery
H. Kimura (2001)
10.1016/J.ADDR.2006.07.027
Challenges and obstacles of ocular pharmacokinetics and drug delivery.
A. Urtti (2006)
10.1002/jps.22813
Novel surface-modified nanostructured lipid carriers with partially deacetylated water-soluble chitosan for efficient ocular delivery.
Baocheng Tian (2012)
10.1016/j.msec.2014.04.049
Drug delivery vehicles on a nano-engineering perspective.
B. Felice (2014)
10.1517/14712598.3.1.45
Drug delivery to the retina: challenges and opportunities
Sridhar Duvvuri (2003)
10.1021/JS9802594
Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye.
M. Prausnitz (1998)
10.1016/j.ejpb.2008.09.003
Lipid nanoparticles for parenteral delivery of actives.
Medha D. Joshi (2009)
Ocular anatomy and physiology
Al Lens (1999)
10.1016/J.ADDR.2007.04.007
Solid lipid nanoparticles as a drug delivery system for peptides and proteins.
A. Almeida (2007)
10.3109/02713681003760168
Feasibility of Lipid Nanoparticles for Ocular Delivery of Anti-Inflammatory Drugs
E. Souto (2010)
10.1016/j.ijpharm.2016.07.031
Dendrimers as a promising tool in ocular therapeutics: Latest advances and perspectives.
J. Rodríguez Villanueva (2016)
10.1080/10611860802228673
Preparation and characterization of diphtheria toxoid-loaded elastic vesicles for transcutaneous immunization
Z. Ding (2008)
10.1146/annurev.anchem.1.031207.112747
Liposomes: technologies and analytical applications.
A. Jesorka (2008)
10.1016/j.jconrel.2007.11.016
Charged nanoparticles delivery to the eye using hydrogel iontophoresis.
E. Eljarrat-Binstock (2008)
10.1128/AAC.33.5.736
Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
M. Jacobson (1989)
A COMPLETE REVIEW ON : LIPOSOMES
K. Shashi (2012)
10.1016/j.jconrel.2009.02.020
Design and evaluation of a liposomal delivery system targeting the posterior segment of the eye.
K. Hironaka (2009)
10.1016/j.ijpharm.2017.04.010
Cyclodextrins and topical drug delivery to the anterior and posterior segments of the eye.
T. Loftsson (2017)
10.1016/J.ADDR.2003.12.002
Solid lipid nanoparticles for parenteral drug delivery.
S. Wissing (2004)
10.2147/IJN.S68861
Liposomes as nanomedical devices
G. Bozzuto (2015)
10.2147/IJN.S25468
Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye
Jayaganesh V. Natarajan (2012)
10.1016/0002-9394(85)90842-6
Common Eye Diseases and Their Management
N. Galloway (1985)
Topical immunization: Mechanistic insight and novel delivery systems
P. N. Gupta (2004)
10.1016/j.ejpb.2016.10.015
Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues.
Sai Prachetan Balguri (2016)
10.1016/j.preteyeres.2013.04.001
Nanomedicines for back of the eye drug delivery, gene delivery, and imaging
U. Kompella (2013)
10.2147/OPTH.S17419
Dexamethasone intravitreal implant for the treatment of noninfectious uveitis
R. S. Hunter (2011)
10.1007/s11095-007-9342-0
Binding of Betaxolol, Metoprolol and Oligonucleotides to Synthetic and Bovine Ocular Melanin, and Prediction of Drug Binding to Melanin in Human Choroid-Retinal Pigment Epithelium
L. Pitkänen (2007)
10.1016/S0074-7696(03)31001-0
Role of mucins in the function of the corneal and conjunctival epithelia.
I. Gipson (2003)
10.1016/S0928-0987(00)00087-7
Transport of drugs from the nasal cavity to the central nervous system.
L. Illum (2000)
10.1002/wnan.1473
Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases.
R. Bisht (2018)
10.2174/138920012798356934
PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery.
P. Milla (2012)
10.1038/eye.2012.199
Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes
D. Lyall (2012)
10.1002/wnan.1272
Controlled ocular drug delivery with nanomicelles.
Ravi Vaishya (2014)
10.1080/03639040801965079
Elastic Liposomal Formulation for Sustained Delivery of Antimigraine Drug: In Vitro Characterization and Biological Evaluation
Twinkal Garg (2008)
10.1016/J.MOLLIQ.2014.09.035
Driving forces and electronic structure in β-cyclodextrin/3,3′-diaminodiphenylsulphone complex
Mohamed Rahim (2014)
10.1111/J.1365-201X.1968.TB10890.X
A method to determine osmotically effective albumin and gammaglobulin concentrations in tissue fluids, its application to the uvea and a note on the effects of capillary "leaks" on tissue fluid dynamics.
A. Bill (1968)
10.1097/OPX.0B013E3181BAFCA3
Ocular Anatomy and Physiology (2nd ed.)
J. Ng (2009)
10.18240/ijo.2018.06.23
Nanotechnology in retinal drug delivery.
S. Jiang (2018)
10.1167/IOVS.05-0189
Characterization of brimonidine transport in retinal pigment epithelium.
N. Zhang (2006)
10.1016/S0002-9394(98)00436-X
Aqueous humor dynamics in the aging human eye.
C. Toris (1999)
10.1517/17425247.1.1.99
Periocular routes for retinal drug delivery
Swita Raghava (2004)
10.1080/08820530902800397
The Effects of Intravitreal Ophthalmic Medications on Intraocular Pressure
H. Wu (2009)
10.1152/PHYSREV.1975.55.3.383
Blood circulation and fluid dynamics in the eye.
A. Bill (1975)
10.1089/jop.2017.0099
Characterization and Pharmacokinetics of Triamcinolone Acetonide-Loaded Liposomes Topical Formulations for Vitreoretinal Drug Delivery.
J. C. Altamirano-Vallejo (2018)
10.1208/s12248-010-9183-3
Ocular Drug Delivery
Ripal Gaudana (2010)
10.1001/ARCHOPHT.1989.01070020849025
Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy.
M. H. Heinemann (1989)
10.1016/j.nano.2015.09.004
Nanostructured lipid carriers: Promising drug delivery systems for future clinics.
A. Beloqui (2016)
10.1023/A:1014474414097
Targeting Vaccines to Dendritic Cells
C. Foged (2004)
10.1016/J.PHARMTHERA.2006.05.006
Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery.
N. Nishiyama (2006)
10.1208/s12249-016-0609-9
Improvement of the Ocular Bioavailability of Econazole Nitrate upon Complexation with Cyclodextrins
A. H. A. Abd El-Gawad (2016)
10.1006/EXER.2000.0909
The effect of hydration and matrix composition on solute diffusion in rabbit sclera.
O. Boubriak (2000)
10.1016/j.colsurfb.2009.09.001
Biodegradable polymeric nanoparticles based drug delivery systems.
A. Kumari (2010)
10.1002/JPS.2600760802
Physicochemical determinants of drug diffusion across the conjunctiva, sclera, and cornea.
I. Ahmed (1987)
10.1016/j.ajps.2017.03.002
Feasibility of drug delivery to the eye's posterior segment by topical instillation of PLGA nanoparticles
Kohei Tahara (2017)
10.2174/1877912311202020082
Novel Nanomicellar Formulation Approaches for Anterior and Posterior Segment Ocular Drug Delivery.
K. Cholkar (2012)
10.1208/s12249-014-0244-2
Nanomicellar Topical Aqueous Drop Formulation of Rapamycin for Back-of-the-Eye Delivery
K. Cholkar (2014)
P-glycoprotein expression in human retinal pigment epithelium.
B. G. Kennedy (2002)
10.1016/j.ejpb.2015.02.032
Undefined role of mucus as a barrier in ocular drug delivery.
M. Ruponen (2015)
10.1097/IAE.0B013E31822C290F
PHARMACOKINETIC RATIONALE FOR DOSING EVERY 2 WEEKS VERSUS 4 WEEKS WITH INTRAVITREAL RANIBIZUMAB, BEVACIZUMAB, AND AFLIBERCEPT (VASCULAR ENDOTHELIAL GROWTH FACTOR TRAP-EYE)
M. Stewart (2012)
10.1016/j.drudis.2010.12.004
Drug delivery to the posterior segment of the eye.
T. R. Thrimawithana (2011)
10.1016/S0939-6411(97)00166-5
Significance of melanin binding and metabolism in the activity of 5-acetoxyacetylimino-4-methyl-delta2-1,3,4,-thiadiazolin e-2-sulfonamide.
R. Schoenwald (1998)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar